Your browser doesn't support javascript.
loading
A distinct core regulatory module enforces oncogene expression in KMT2A-rearranged leukemia.
Harada, Taku; Heshmati, Yaser; Kalfon, Jérémie; Perez, Monika W; Xavier Ferrucio, Juliana; Ewers, Jazmin; Hubbell Engler, Benjamin; Kossenkov, Andrew; Ellegast, Jana M; Yi, Joanna S; Bowker, Allyson; Zhu, Qian; Eagle, Kenneth; Liu, Tianxin; Kai, Yan; Dempster, Joshua M; Kugener, Guillaume; Wickramasinghe, Jayamanna; Herbert, Zachary T; Li, Charles H; Vrabic Koren, Jost; Weinstock, David M; Paralkar, Vikram R; Nabet, Behnam; Lin, Charles Y; Dharia, Neekesh V; Stegmaier, Kimberly; Orkin, Stuart H; Pimkin, Maxim.
Afiliação
  • Harada T; Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
  • Heshmati Y; Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
  • Kalfon J; Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts 02142, USA.
  • Perez MW; Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
  • Xavier Ferrucio J; Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
  • Ewers J; Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
  • Hubbell Engler B; Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
  • Kossenkov A; The Wistar Institute, Philadelphia, Pennsylvania 19104, USA.
  • Ellegast JM; Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
  • Yi JS; Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts 02142, USA.
  • Bowker A; Baylor College of Medicine, Houston, Texas 77030, USA.
  • Zhu Q; Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
  • Eagle K; Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
  • Liu T; Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
  • Kai Y; Ken Eagle Consulting, Houston, Texas 77494, USA.
  • Dempster JM; Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
  • Kugener G; Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
  • Wickramasinghe J; Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts 02142, USA.
  • Herbert ZT; Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts 02142, USA.
  • Li CH; The Wistar Institute, Philadelphia, Pennsylvania 19104, USA.
  • Vrabic Koren J; Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02215, USA.
  • Weinstock DM; Whitehead Institute for Biomedical Research, Cambridge, Massachusetts 02142, USA.
  • Paralkar VR; Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA.
  • Nabet B; Baylor College of Medicine, Houston, Texas 77030, USA.
  • Lin CY; Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02215, USA.
  • Dharia NV; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
  • Stegmaier K; Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA.
  • Orkin SH; Baylor College of Medicine, Houston, Texas 77030, USA.
  • Pimkin M; Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
Genes Dev ; 36(5-6): 368-389, 2022 03 01.
Article em En | MEDLINE | ID: mdl-35301220
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Proteína de Leucina Linfoide-Mieloide Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Proteína de Leucina Linfoide-Mieloide Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article